In cells with HER2 gene amplification, sensitivity to lapatinib is associated with higher overexpression of HER2 and EGFR [47]; thus, sensitivity to lapatinib has been used to identify BC cell lines that are dependent on the HER2 oncogene for growth (HER2 addicted) [48]. This evidence concerns the gene EGFR and breast cancer.